ArticleBiotechnology and bioengineering2012
Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair.
Article in Biotechnology and bioengineering, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Microneedle patches: the next frontier in cardiovascular care.Drug delivery and translational research · 2025Review
- A continuum model and simulations for large deformation of anisotropic fiber-matrix composites for cardiac tissue engineering.Journal of the mechanical behavior of biomedical materials · 2021Article
- Improved Left Ventricular Aneurysm Repair with Cell- and Cytokine-Seeded Collagen Patches.Stem cells international · 2018Article
- Tissue Engineering Strategies for Myocardial Regeneration: Acellular Versus Cellular Scaffolds?Tissue engineering. Part B, Reviews · 2016Review
- A novel platelet lysate hydrogel for endothelial cell and mesenchymal stem cell-directed neovascularization.Acta biomaterialia · 2016Article
- iPSC-derived human mesenchymal stem cells improve myocardial strain of infarcted myocardium.Journal of cellular and molecular medicine · 2014Article
- Current status of induced pluripotent stem cells in cardiac tissue regeneration and engineering.Regenerative medicine research · 2013Review
- Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms.Stem cell reviews and reports · 2013Review
- Mesenchymal stem cells in tumor development: emerging roles and concepts.Cell adhesion & migrationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Human mesenchymal stem cells (hMSC) have proven beneficial in the repair and preservation of infarcted myocardium. Unfortunately, MSCs represent a small portion of the bone marrow and require ex vivo expansion. To further advance the clinical usefulness of cellular cardiomyoplasty, derivation of "MSC-like" cells that can be made available "off-the-shelf" are desirable. Recently, human embryonic stem cell-derived mesenchymal cells (hESC-MC) were described. We investigated the efficacy of hESC-MC for cardiac repair after myocardial infarction (MI) compared to hMSC. Because of increased efficacy of cell delivery, cells were embedded into collagen patches and delivered to infarcted myocardium. Culture of hMSC and hESC-MCs in collagen patches did not induce differentiation or significant loss in viability. Transplantation of hMSC and hES-MC patches onto infarcted myocardium of athymic nude rats prevented adverse changes in infarct wall thickness and fractional area change compared to a non-viable patch control. Hemodynamic assessment showed that hMSCs and hES-MC patch application improved end diastolic pressure equivalently. There were no changes in systolic function. hES-MC and hMSC construct application enhanced neovessel formation compared to a non-viable control, and each cell type had similar efficacy in stimulating endothelial cell growth in vitro. In summary, the use of hES-MC provides similar efficacy for cellular cardiomyoplasty as compared to hMSC and may be considered a suitable alternative for cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.